You are here
ARMAGEN TECHNOLOGIES, INC.
UEI: N/A
# of Employees: 9
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome
Amount: $1,033,433.00DESCRIPTION provided by applicant Type IIIA Mucopolysaccharidosis MPS also known as Sanfilippo A syndrome is a genetic disease that affects the lysosomal enzyme N sulfoglucosamine sulfohydrola ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome
Amount: $152,138.00DESCRIPTION (provided by applicant): Mucopolysaccharidosis (MPS) Type IIIA, also called Sanfilippo A syndrome, is a genetic disease caused by mutations in the gene encoding the lysosomal enzyme, N-su ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Manufacturing of Trojan Horse-TNFR Decoy Receptor Fusion Protein
Amount: $981,134.00DESCRIPTION (provided by applicant): Tumor necrosis factor (TNF)-alpha plays a pro-inflammatory role in aging-related neurodegenerative diseases, such as Alzheimer's disease or Parkinson's ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Metachromatic Leukodystrophy Enzyme Drug Development
Amount: $999,645.00DESCRIPTION (provided by applicant): Metachromatic Leukodystrophy or MLD, is a genetic disease that affects the lysosomal enzyme, arylsulfatase A (ASA). People born with MLD develop extensive lysosoma ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Enzyme replacement therapy of the brain in Mucopolysaccharidosis Type II
Amount: $1,052,435.00DESCRIPTION (provided by applicant): Type II Mucopolysaccharidosis (MPS), also known as Hunter's syndrome, is a genetic disease that affects the lysosomal enzyme, iduronate-2-sulfatase (IDS). Con ...
SBIRPhase II2012Department of Health and Human Services National Institutes of Health -
Manufacturing of Trojan Horse-TNFR Decoy Receptor Fusion Protein
Amount: $148,530.00DESCRIPTION (provided by applicant): Tumor necrosis factor (TNF)- plays a pro-inflammatory role in brain diseases. The biologic TNF inhibitors (TNFI), such as the TNF decoy receptor cannot be develop ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Metachromatic Leukodystrophy Enzyme Drug Development
Amount: $156,555.00DESCRIPTION (provided by applicant): Metachromatic leukodystrophy (MLD) is an genetic disease caused by mutations in the gene encoding the lysosomal enzyme, arylsulfatase A (ASA). Symptoms including n ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Enzyme replacement therapy of the brain in Mucopolysaccharidosis Type II
Amount: $111,214.00DESCRIPTION (provided by applicant): Type II Mucopolysaccharidosis (MPS), also known as Hunter's syndrome, is an genetic disease that affects the lysosomal enzyme, iduronate-2-sulfatase (IDS). C ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Re-Engineering Blood-Borne Erythropoietin for Targeted Delivery
Amount: $149,800.00DESCRIPTION (provided by applicant): Erythropoietin (EPO) is a potential new pharmaceutical to treat vascular disease of the brain, including stroke. However, EPO is a large molecule pharmaceutical th ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Bioengineering of a New Antibody Drug Delivery Technology
Amount: $849,582.00DESCRIPTION (provided by applicant): Monoclonal antibodies (MAb) are potential new therapeutics for many brain diseases, including Alzheimer's disease (AD), Parkinson's disease, mad cow dise ...
SBIRPhase II2011Department of Health and Human Services National Institutes of Health